1.
Artículo
en Inglés
| IMSEAR
| ID: sea-111421
RESUMEN
A few years back, the survival benefit of trastuzumab in HER 2 positive breast cancer patients presenting with metastatic disease was proven in a randomized setting. Recently a number of randomized trials have reported their results in the adjuvant setting in HER 2 positive patients. These trials have been considered by some as a landmark in the evolution of breast cancer management. Although the data is encouraging, it need to be seen in a proper perspective keeping in mind the limitations and the side effects reported. This article stresses the use of Herceptin in carcinoma breast patients in adjuvant setting with a cautionary eye.
Asunto(s)
Anticuerpos Monoclonales/economía , Antineoplásicos/economía , Neoplasias de la Mama/tratamiento farmacológico , Quimioterapia Adyuvante , Femenino , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Receptor ErbB-2/efectos de los fármacos
2.
Rev. argent. mastología
;
13(40): 79-82, jul. 1994.
Artículo
en Español
| LILACS
| ID: lil-180709